S033 Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will review hidradenitis suppurativa (HS) epidemiology and comorbidities, and current concepts of pathogenesis. An evidence-based approach for the use of medical therapies for HS, including topical agents, antibiotics, non-antibiotic systemics, biologics, small molecule inhibitors and pain management, will be discussed. An evidence-based approach for the use of surgical therapies for HS, including office-based procedures and laser therapy, will be reviewed. The patient perspective of living with HS and an approach to optimize clinic visits and helping HS patients access needed therapies will also be presented.
LEARNING OBJECTIVES
Describe the pathophysiology, epidemiology and comorbidities of hidradenitis suppurativa.
Apply appropriate medical, procedural and pain management strategies for hidradenitis suppurativa.
Recognize the patient experience of living with hidradenitis suppurativa, and apply effective strategies to optimize clinic visits and increase treatment access for people with HS.
SCHEDULE
5:00 PM
Introduction
Haley Naik, MD, FAAD
5:05 PM
Living with Hidradenitis Suppurativa
5:15 PM
Optimizing the HS Clinic Visit
Leandra Alicia Barnes, MD, FAAD
5:30 PM
Overcoming Barriers to Therapeutic Access
Tiffany Mayo, MD, FAAD
5:45 PM
Epidemiology and Comorbidities of HS
Ra'ed Alhusayen, MD, MSc, FAAD
6:00 PM
Pathophysiology of HS
John Frew, MBBS, IFAAD
6:15 PM
Moderated Q&A
Ra'ed Alhusayen, MD, MSc, FAAD, Leandra Alicia Barnes, MD, FAAD, John Frew, MBBS, IFAAD, Tiffany Mayo, MD, FAAD
6:30 PM
HS Pain Management
Lauren Orenstein, MD, FAAD
6:45 PM
HS Medical Management with Biologics and Small Molecule Inhibitors
Robert Micheletti, MD, FAAD
7:05 PM
HS Medical Management with Non-Biologic Medications
Haley Naik, MD, FAAD
7:20 PM
Office-based Surgical Procedures for HS
Daniel Mark Klufas, MD, FAAD
7:40 PM
Moderated Q&A
Haley Naik, MD, FAAD, Daniel Mark Klufas, MD, FAAD, Robert Micheletti, MD, FAAD, Lauren Orenstein, MD, FAAD
7:55 PM
Conclusion
Haley Naik, MD, FAAD
SPEAKERS
Ra'ed Alhusayen, MD, MSc, FAAD
Leandra Alicia Barnes, MD, FAAD
Mark Dixon
John Frew, MBBS, IFAAD
Daniel Mark Klufas, MD, FAAD
Tiffany Mayo, MD, FAAD
Robert Micheletti, MD, FAAD
Haley Naik, MD, FAAD
Lauren Orenstein, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Ra'ed Alhusayen, MD, MSc, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Bausch Health – Investigator(Fees), Investigator(Grants/Research Funding); Canadian Dermatology Association – Board of Directors(No Compensation Received); Canadian Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Fresenius Kabi – Advisory Board(Honoraria); Incyte – Investigator(Fees), Investigator(Grants/Research Funding); janssen – Advisory Board(Honoraria), Investigator(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sandoz Pharmaceuticals AG – Advisory Board(Honoraria); Sun Pharma Advanced Research Company (SPARC) – Advisory Board(Honoraria); UCB Pharma – Advisory Board(Honoraria);
Leandra Alicia Barnes, MD, FAAD
No financial relationships exist with ineligible companies.
Mark Dixon
No financial relationships exist with ineligible companies.
John Frew, MBBS, IFAAD
No financial relationships exist with ineligible companies.
Daniel Mark Klufas, MD, FAAD
No financial relationships exist with ineligible companies.
Tiffany Mayo, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); Acelyrin – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);
Robert Micheletti, MD, FAAD
Acelyrin – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); InflaRx – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Haley Naik, MD, FAAD
23andMe – Consultant(Honoraria); AbbVie – Consultant(Honoraria), Other(Grants/Research Funding); Aristea Therapeutics, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Dava Oncology – Consultant(Honoraria); Johnson and Johnson – Consultant(Honoraria); Medscape – Consultant (1099 relationship)(Fees); Nimbus Therapeutics – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Radera Biotherapeutics, Inc. – Stockholder Private Company(Stock Options); Radera, Inc. – Stockholder Private Company(Stock Options); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant (1099 relationship)(Fees);
Lauren Orenstein, MD, FAAD
HS Foundation – Board of Directors(No Compensation Received); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Phrase Health – Stockholder(Stock); UCB Pharma – Advisory Board(Fees);